IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS,

Status Recruiting

Clinical Trial Summary

This study will enroll patients with small fiber neuropathy (SFN). The study will look at an intravenous immunoglobulin (IVIG) called Panzyga. Panzyga is approved by the FDA as a therapy for Primary humoral immunodeficiency (PI) in patients 2 years of age and older; Chronic immune thrombocytopenia (ITP) in adults and Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. It has not been approved by the FDA for use in SFN. There is mounting evidence that Intravenous Immunoglobulin (IVIG) can cause pain reduction and improve objective nerve fiber densities on skin biopsies in great numbers in SFN patients. The primary outcome is quantified improvement in intraepidermal nerve fiber density (IENFD) on repeat skin punch biopsy after 6 months of IVIG treatment.

Clinical Trial Description

Small fiber neuropathy (SFN) is an increasingly prevalent diagnosis in neurology and neuromuscular centers. Modern diagnostic techniques, including skin biopsies and autonomic nervous testing are helping to find SFN in many patients with undiagnosed pain syndromes including fibromyalgia. The prevalence is rising for SFN, and an immune etiology may underlie 19%-34% of cases. While there is no standard of care treatment, current treatment strategies for SFN include long-term steroid therapy which come with a host of side effects. There is mounting evidence that Intravenous Immunoglobulin (IVIG) can cause pain reduction and improve objective nerve fiber densities on skin biopsies in great numbers in SFN patients, as well as improving validated questionnaire scores monitoring symptom burden and disability. However, neither IVIG nor any other immunosuppressant has been studied in a sufficiently powered and adequately dosed controlled, randomized clinical trial to demonstrate efficacy. ;

Study Design

Related Conditions & MeSH terms

Autoimmune Small Fiber Neuropathy
Immune-Mediated Neuropathy
Inflammatory Polyneuropathy
Peripheral Nervous System Diseases
Polyneuropathies
Small Fiber Neuropathy

Clinical Trial Details

NCT number	NCT04153422
Study type	Interventional
Source	Henry Ford Health System
Contact	Kate Swiftney, RN
Phone	313-916-3501
Email	kswiftn1@hfhs.org
Status	Recruiting
Phase	Phase 2
Start date	December 15, 2023
Completion date	April 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02537951` - Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study	N/A
Completed	`NCT01911975` - Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	Phase 3
Completed	`NCT03304522` - A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy	Phase 2
Recruiting	`NCT04310644` - Autonomic Small Fiber Neuropathy and Ehlers Danlos Syndromes - Prospective Study and Registry
Completed	`NCT03912220` - Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration	Phase 2
Completed	`NCT03401073` - IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3	Phase 2
Recruiting	`NCT03889080` - fMRI-study in Patients With Small Fiber Neuropathy
Completed	`NCT03447756` - Titration Study of ABX-1431	Phase 1
Recruiting	`NCT04835779` - Biometric and Biological Data for Diagnosis and Therapy of Pain Patients
Suspended	`NCT04611048` - Establishing Normative Values for Thermal Detection and Pain Threshold Established by the Psi Method	N/A
Not yet recruiting	`NCT04170205` - Causes Associated With Small Fiber Neuropathy (SFN).
Recruiting	`NCT05389566` - Diabetes, Falls, and Fractures
Terminated	`NCT03339336` - Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy	Phase 2
Recruiting	`NCT05798949` - Chronic Pain Rehabilitation in Patients With Small Fiber Neuropathy	N/A
Enrolling by invitation	`NCT05921097` - Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes
Completed	`NCT02637700` - Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy	Phase 2
Recruiting	`NCT04759443` - Detection of Small Fiber Neuropathy Using Skin Properties
Terminated	`NCT02905396` - Spinal Cord Stimulation in Small Fibre Neuropathy	N/A
Completed	`NCT05380804` - Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
Recruiting	`NCT03509064` - Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms